OpenNashEarnings

Moderna (MRNA) · Biotechnology

Moderna Q2 2026 earnings: summary, key numbers & outlook

Results filed 31 Jul 2026 · Quarter ended 30 Jun 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Moderna is awaiting a U.S. decision on its seasonal flu vaccine mFLUSIVA, which would be its fifth product, after a unanimous advisory committee recommendation, while its norovirus vaccine missed an early-success bar.

Moderna's flu vaccine mFLUSIVA won a unanimous FDA advisory committee recommendation ahead of an August 5 decision date, and the flu-plus-COVID shot mCOMBRIAX gained European Commission authorization. mRESVIA was approved in Australia and Mexico and mNEXSPIKE in Japan and Taiwan. Europe added a joint procurement contract for up to 24 million mRESVIA doses on behalf of six countries, and a Brazil manufacturing collaboration supports COVID vaccine supply. The norovirus vaccine did not meet early-success criteria at its interim analysis.

Management is steering toward a broader, more diversified portfolio: flu approvals, international partnerships, and pivotal readouts in 2026 for intismeran in melanoma and for the propionic acidemia therapy. The tension is that growth depends on a few binary events, including the U.S. flu decision, FDA guidance on refiling the combination vaccine, and COVID vaccination rates that may keep falling, while the norovirus program now needs another cohort.

No call transcript for this quarter, so this summary also draws on: Mitrade (transcript sourced from The Motley Fool) ↗.

Key numbers

Total revenue · GAAP
$145 million

compared to $142 million in the same period in 2025

Net loss · GAAP
$(0.8) billion

an improvement of $43 million, or 5%, compared to the second quarter of 2025

Loss per share · GAAP
$(1.97)

compared to $(2.13) for the second quarter of 2025

Loss from operations · GAAP
-815.0M

compared to (907) in the second quarter of 2025

Cash, cash equivalents and investments
$6.9 billion

compared to $7.5 billion as of March 31, 2026

Segment or metricValueChange
U.S. revenue$87 million
International revenue$58 million
Net product sales$94.0Mcompared to $114 in the second quarter of 2025
Where each number comes from
  • Total revenue: “Total revenue for the second quarter of 2026 was $145 million, compared to $142 million in the same period in 2025.”
  • Net loss: “Net loss was $(0.8) billion for the second quarter of 2026, an improvement of $43 million, or 5%, compared to the second quarter of 2025.”
  • Loss per share: “Loss per share was $(1.97) for the second quarter of 2026, compared to loss per share of $(2.13) for the second quarter of 2025.”
  • Loss from operations: “Loss from operations | (815) | (907) | (2,203) | (1,957) Interest income | 67 | 81 | 139 | 171”
  • Cash, cash equivalents and investments: “Cash, cash equivalents and investments as of June 30, 2026, were $6.9 billion, compared to $7.5 billion as of March 31, 2026.”
  • U.S. revenue: “Revenue was $87 million in the U.S. and $58 million in international markets.”
  • International revenue: “Revenue was $87 million in the U.S. and $58 million in international markets.”
  • Net product sales: “Net product sales | $94 | $114 | $446 | $200 Other revenue1 | 51 | 28 | 88 | 50 Total revenue | 145 | 142 | 534 | 250”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$145.0M+2.1%−62.7%
Operating income-$815.0M+10.1%+41.3%
Net income-$782.0M+5.2%+41.8%
Diluted EPS-$1.97+7.5%+42.1%
Free cash flow-$563.0M+38.9%+18.6%
Operating margin-562.1%+76.6 pts−205.3 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Revenue growth from 20252026up to 10%
Share of second half revenue in the third quartersecond half of 2026approximately 55%
Cost of sales2026approximately $1.7 billion
Research and development expenses2026approximately $2.9 billion
Selling, general and administrative expenses2026approximately $1.0 billion
Capital expenditures2026$0.2 to $0.3 billion
Year-end cash and investmentsyear-end 2026$4.7 to $5.2 billion

Key takeaways

  1. mFLUSIVA could become Moderna's fifth approved product

    The seasonal flu vaccine received a unanimous VRBPAC recommendation ahead of an August 5 PDUFA date. Approval would extend Moderna beyond COVID and RSV in the U.S.

  2. Norovirus vaccine missed early-success bar at interim

    mRNA-1403 did not meet statistical criteria for early success in Phase 3. The trial remains blinded and Moderna is preparing to enroll an additional cohort, which delays any answer.

  3. International partnerships and approvals widen the commercial base

    Moderna signed a joint EU procurement contract for up to 24 million mRESVIA doses and a Brazil manufacturing collaboration for COVID vaccines. New approvals came in Australia, Mexico, Japan and Taiwan.

  4. Combination flu and COVID vaccine advances outside the U.S.

    mCOMBRIAX received European Commission authorization and mRNA-1083 filings are under review in Japan, Canada and Australia. In the U.S., Moderna is still awaiting FDA guidance on refiling.

  5. Intismeran oncology program expands toward pivotal data

    Nine Phase 2 and Phase 3 trials with Merck are underway, and five-year Phase 2b melanoma data showed a 49% lower risk of recurrence or death versus KEYTRUDA alone. Phase 3 adjuvant melanoma data are potentially due in 2026.

Charts

Revenue$145.0M+2.1% y/yQ2 2026
Q4 2024: $966.0M (worked out from the annual figure)Q4 ’24$966.0MQ1 2025: $108.0MQ1 ’25$108.0MQ2 2025: $142.0MQ2 ’25$142.0MQ3 2025: $1.0BQ3 ’25$1.0BQ4 2025: $678.0M (worked out from the annual figure)Q4 ’25$678.0MQ1 2026: $389.0MQ1 ’26$389.0MQ2 2026: $145.0MQ2 ’26$145.0MQ3 2026: $1.3BQ3 ’26$1.3B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$966.0M *
Q1 2025$108.0M
Q2 2025$142.0M
Q3 2025$1.0B
Q4 2025$678.0M *
Q1 2026$389.0M
Q2 2026$145.0M
Q3 2026$1.3B
Diluted EPS (GAAP)-$1.97+7.5% y/yQ2 2026
Q1 2025: -$2.52Q1 ’25-$2.52Q2 2025: -$2.13Q2 ’25-$2.13Q3 2025: -$0.51Q3 ’25-$0.51Q1 2026: -$3.40Q1 ’26-$3.40Q2 2026: -$1.97Q2 ’26-$1.97Q3 2026: $0.38Q3 ’26$0.38
Data
Q1 2025-$2.52
Q2 2025-$2.13
Q3 2025-$0.51
Q1 2026-$3.40
Q2 2026-$1.97
Q3 2026$0.38

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin-562.1%+76.6 pts y/yQ2 2026
Q4 2024: -129.0%Q4 ’24-129.0%Q1 2025: -972.2%Q1 ’25-972.2%Q2 2025: -638.7%Q2 ’25-638.7%Q3 2025: -25.6%Q3 ’25-25.6%Q4 2025: -126.4%Q4 ’25-126.4%Q1 2026: -356.8%Q1 ’26-356.8%Q2 2026: -562.1%Q2 ’26-562.1%Q3 2026: 9.9%Q3 ’269.9%
Data
Q4 2024-129.0%
Q1 2025-972.2%
Q2 2025-638.7%
Q3 2025-25.6%
Q4 2025-126.4%
Q1 2026-356.8%
Q2 2026-562.1%
Q3 20269.9%
Free cash flow-$563.0M+38.9% y/yQ2 2026
Q4 2024: $303.0MQ4 ’24$303.0MQ1 2025: -$1.2BQ1 ’25-$1.2BQ2 2025: -$922.0MQ2 ’25-$922.0MQ3 2025: -$880.0MQ3 ’25-$880.0MQ4 2025: $891.0MQ4 ’25$891.0MQ1 2026: -$692.0MQ1 ’26-$692.0MQ2 2026: -$563.0MQ2 ’26-$563.0MQ3 2026: -$1.6BQ3 ’26-$1.6B
Data
Q4 2024$303.0M
Q1 2025-$1.2B
Q2 2025-$922.0M
Q3 2025-$880.0M
Q4 2025$891.0M
Q1 2026-$692.0M
Q2 2026-$563.0M
Q3 2026-$1.6B

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What is the next major U.S. catalyst for Moderna's product portfolio?

The FDA decision on mFLUSIVA, its seasonal flu vaccine, with a PDUFA date of August 5, 2026. Approval would make it Moderna's fifth approved product.

What happened with Moderna's norovirus vaccine?

Phase 3 mRNA-1403 did not meet statistical criteria for early success at the interim analysis. The trial is ongoing and blinded while Moderna works toward enrolling an additional cohort.

Where is Moderna expanding its vaccine business outside the U.S.?

It signed a joint EU procurement contract for up to 24 million mRESVIA doses for six countries and a Brazil manufacturing collaboration for COVID vaccines. It also received approvals in Australia, Mexico, Japan and Taiwan.

What is the status of Moderna's flu plus COVID combination vaccine?

mCOMBRIAX is authorized in the EU, and mRNA-1083 filings are under review in Japan, Canada and Australia. Moderna is awaiting FDA guidance on refiling in the U.S.

What pivotal readouts is Moderna expecting in 2026?

Phase 3 adjuvant melanoma data for intismeran, developed with Merck, and registrational data for its propionic acidemia therapy mRNA-3927. Moderna deferred a pivotal trial decision on its methylmalonic acidemia candidate until the PA readout.

Documents

SEC filing